summary: This study demonstrates that peripheral phosphodiesterase 4 inhibition, produced by a compound labeled as L-826,141, prevents the progression of autoimmune encephalomyelitis, an animal model of multiple sclerosis after the first onset of clinical signs, and suggests that similar compounds may have clinical efficacy in the treatment of MS.

authors: Moore CS, Owens T, Earl N, Frenette R, Styhler A, Nicholson DW, Mancini JA, Hebb AL, Robertson GS.

source: J Pharmacol Exp Ther. 2006 Jun 29; [Epub ahead of print]

weblink: click here

category: Clinical Trials and Therapeutics

related research news: click here

glossary: